Findings

What do systematic reviews say?

4,734 questions · 15,288 findings · 893 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,864 · 25.3%GRADE not reported 2,222 · 14.5%Very low 3,868 · 25.3%Low 3,280 · 21.5%Moderate 1,676 · 11%High 378 · 2.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

HD‐ICS (Direct evidence; 2 RCTs; 1011 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1011 participants
Moderate

Intervention not reported

MD‐ICS/LABA (Direct evidence; 1 RCT; 774 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 774 participants
Moderate

Intervention not reported

HD‐ICS/LABA (Direct evidence; 1 RCT; 1167 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1167 participants
High

Intervention not reported

MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA, or HD‐ICS/LABA…

The review found no eligible studies for this question.

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 34 RCTs Total participants: 32,684 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
34 studies · 32684 participants
GRADE not reported

Intervention not reported

HD‐ICS (Direct evidence; 6 RCTs; 2211 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 2211 participants
High

Intervention not reported

LD‐ICS/LABA (Direct evidence; 1 RCT; 5846 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 5846 participants
High

Intervention not reported

MD‐ICS/LAMA (Direct evidence; 1 RCT; 282 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
Low

Intervention not reported

MD‐ICS/LAMA (Direct evidence; 4 RCTs; 2239 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2239 participants
Moderate

Intervention not reported

MD‐ICS/LABA (Direct evidence; 21 RCTs; 20326 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
21 studies · 20326 participants
High

Intervention not reported

HD‐ICS/LABA (Direct evidence; 4 RCTs; 2750 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2750 participants
High

Intervention not reported

MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

The review found no eligible studies for this question.

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA (Direct evidence; 10 RCTs; 15,651 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 15651 participants
Moderate

Intervention not reported

HD‐ICS/LABA (Direct evidence; 3 RCTs; 3319 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3319 participants
Low

Intervention not reported

MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

The review found no eligible studies for this question.

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 25 RCTs Total participants: 25,583 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
25 studies · 25583 participants
GRADE not reported

Intervention not reported

HD‐ICS (Direct evidence; 4 RCTs; 1685 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1685 participants
Moderate

Intervention not reported

Total studies: 42 Total participants: 14,626 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…

The intervention led to lower total studies: 42 Total participants: 14,626; GRADE not reported.

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
42 participants
GRADE not reported

Intervention not reported

Desvenlafaxine high dose RCTs: 2 Participants: 870 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 participants
Very low

Intervention not reported

Total studies: 50 Total participants: 14,926 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
50 participants
GRADE not reported